Wave Life Sciences Ltd.
WVE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.60 | 0.13 | 0.26 | 0.03 |
| FCF Yield | -8.88% | -3.83% | -23.40% | -55.03% |
| EV / EBITDA | -14.09 | -6.25 | -3.28 | -0.36 |
| Quality | ||||
| ROIC | -44.36% | -70.58% | -190.33% | -83.03% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 1.56 | 0.34 | 0.79 | 0.73 |
| Growth | ||||
| Revenue 3-Year CAGR | 209.61% | 40.37% | -43.36% | 36.85% |
| Free Cash Flow Growth | -639.63% | 84.09% | -44.21% | 23.67% |
| Safety | ||||
| Net Debt / EBITDA | 2.72 | 2.86 | 0.33 | 1.03 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 4.79 | 67.93 | 0.00 | 0.00 |